The Ovaries Age Fastest. That May Be the Key to Women's Longevity.
Ask researchers which organ in the body ages fastest, and many will say the ovaries. While the brain, heart, and liver decline gradually over decades, ovarian function drops sharply beginning in the mid-thirties and is largely spent by the early fifties. The problem is that the ovaries are not simply reproductive organs.
When Estrogen Stops, the Whole Body Changes
Estrogen maintains bone density, protects the walls of blood vessels, and supports synaptic plasticity in the brain. When menopause cuts off estrogen production, the consequences ripple outward. Osteoporosis risk rises. Cardiovascular disease rates in women approach those of men. The risk of neurodegeneration increases as well. For a long time, these changes were accepted as the natural course of aging. Recent research is reframing them as a process that may be amenable to early intervention.
One of the key markers of ovarian aging is AMH, or anti-Müllerian hormone. AMH reflects the remaining pool of egg-producing follicles and starts declining in the early thirties. By menopause, it is nearly undetectable. US biotech startup Oviva Therapeutics is investigating whether AMH can be administered directly as a therapeutic, not merely tracked as a biomarker. The hypothesis they are testing is that AMH actively shapes the hormonal environment rather than simply reflecting it, and that supplementing it could slow the decline of ovarian function.
Rapamycin: Early Signals From Animal Studies
Rapamycin, one of the most closely studied molecules in aging science, works by inhibiting a cellular signaling pathway called mTOR, which regulates growth and metabolism. In middle-aged female mice, rapamycin treatment preserved ovarian function, reduced systemic inflammation markers, and extended lifespan. The data are still at the animal stage. Whether the same effects translate to humans requires dedicated clinical trials. But the results add real weight to the hypothesis that slowing ovarian aging could shift the entire trajectory of a woman’s health.
XPRIZE’s $50 Million Bet on Women’s Health
In 2026, XPRIZE announced a $50 million prize specifically for innovations that extend healthy lifespan in post-menopausal women by ten years or more. Beyond the prize money, the program represents something significant: an acknowledgment that longevity science has historically been built on male data.
Major longevity studies have often enrolled fewer women than men. Female-specific biology, particularly the hormonal shifts of menopause, was frequently treated as a confounding variable rather than a central subject of inquiry. Rapamycin, NMN, and senolytic research were largely conducted in male mice first, with women-inclusive human trials following later if at all. The XPRIZE initiative signals a course correction.
Research into what actually helps during and after the menopausal transition is now being conducted across multiple labs simultaneously. Lifestyle factors, hormonal therapies, and novel molecular interventions are all under examination. The core question is whether a woman’s healthspan can be meaningfully decoupled from her reproductive lifespan. Work on that question has only just begun in earnest.